Moulay A Alaoui-Jamali

List of Publications by Year
in descending order

70 papers	4,698 citations	126907 33 h-index	102487 66 g-index
71 all docs	71 docs citations	71 times ranked	7112 citing authors

#	Article	IF	Citations
1	Molecular prognostic indicators in HPV-positive oropharyngeal cancer: an updated review. Clinical and Experimental Metastasis, 2022, 39, 407-416.	3.3	7
2	Novel Aurora A and Protein Kinase C (Î±, Î²1, Î²2, and Î) Multitarget Inhibitors: Impact of Selenium Atoms on the Potency and Selectivity. Journal of Medicinal Chemistry, 2022, 65, 3134-3150.	6.4	8
3	NEDD9 links anaplastic thyroid cancer stemness to chromosomal instability through integrated centrosome asymmetry and DNA sensing regulation. Oncogene, 2022, 41, 2984-2999.	5.9	3
4	Chitosan/PCL nanoparticles can improve anti-neoplastic activity of 5-fluorouracil in head and neck cancer through autophagy activation. International Journal of Biochemistry and Cell Biology, 2021, 134, 105964.	2.8	12
5	Portrait of DNA methylated genes predictive of poor prognosis in head and neck cancer and the implication for targeted therapy. Scientific Reports, 2021, 11, 10012.	3.3	10
6	Co-Overexpression of TWIST1-CSF1 Is a Common Event in Metastatic Oral Cancer and Drives Biologically Aggressive Phenotype. Cancers, 2021, 13, 153.	3.7	12
7	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 502 Td	9.1	1,430
8	Nanoparticle-Based Chemotherapy Formulations for Head and Neck Cancer: A Systematic Review and Perspectives. Nanomaterials, 2020, 10, 1938.	4.1	8
9	Head and neck cancer: Emerging concepts in biomarker discovery and opportunities for clinical translation. Clinical and Translational Medicine, 2020, 10, e209.	4.0	5
10	NDRG1 deficiency is associated with regional metastasis in oral cancer by inducing epithelialâ€“mesenchymal transition. Carcinogenesis, 2020, 41, 769-777.	2.8	12
11	SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors. Cancer Research, 2019, 79, 2761-2774.	0.9	54
12	A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy. Autophagy, 2019, 15, 1376-1390.	9.1	44
13	A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability. Molecular Cancer Research, 2019, 17, 2492-2507.	3.4	63
14	Oncogenic activity of poly (ADP-ribose) glycohydrolase. Oncogene, 2019, 38, 2177-2191.	5.9	21
15	MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ. Cancer Research, 2019, 79, 1646-1657.	0.9	31
16	TRAF2 Cooperates with Focal Adhesion Signaling to Regulate Cancer Cell Susceptibility to Anoikis. Molecular Cancer Therapeutics, 2019, 18, 139-146.	4.1	18
17	Efficacy of hybrid vitamin D receptor agonist/histone deacetylase inhibitors in vitamin D-resistant triple-negative 4T1 breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2018, 177, 135-139.	2.5	10
18	Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer. Nature Communications, 2018, 9, 3598.	12.8	134

#	Article	IF	Citations
19	Ubiquitin ligase RNF8 suppresses Notch signaling to regulate mammary development and tumorigenesis. Journal of Clinical Investigation, 2018, 128, 4525-4542.	8.2	31
20	CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair. Science Advances, 2017, 3, e1601898.	10.3	56
21	Design and validation of an orally administrated active L. fermentum-L. acidophilus probiotic formulation using colorectal cancer Apc Min/+ mouse model. Applied Microbiology and Biotechnology, 2017, 101, 1999-2019.	3.6	50
22	Fascin promotes migration and invasion and is a prognostic marker for oral squamous cell carcinoma. Oncotarget, 2017, 8, 74736-74754.	1.8	34
23	Meta-analysis of microRNAs expression in head and neck cancer: uncovering association with outcome and mechanisms. Oncotarget, 2017, 8, 55511-55524.	1.8	57
24	MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. Journal of Clinical Investigation, 2017, 127, 4179-4192.	8.2	62
25	Endosomal sorting and c-Cbl targeting of paxillin to autophagosomes regulate cell-matrix adhesion turnover in human breast cancer cells. Oncotarget, 2017, 8, 31199-31214.	1.8	14
26	Peroxiredoxin 1 interacts with and blocks the redox factor APE1 from activating interleukin-8 expression. Scientific Reports, 2016, 6, 29389.	3.3	40
27	Insights into a novel nuclear function for Fascin in the regulation of the amino-acid transporter SLC3A2. Scientific Reports, 2016, 6, 36699.	3.3	22
28	microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients. Molecular Biology Reports, 2016, 43, 229-240.	2.3	12
29	Genome-wide targeting of the epigenetic regulatory protein CTCF to gene promoters by the transcription factor TFII-I. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E677-86.	7.1	65
30	ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics. Frontiers in Genetics, 2015, 6, 17.	2.3	32
31	Epithelial-mesenchymal transition (EMT) markers have prognostic impact in multiple primary oral squamous cell carcinoma. Clinical and Experimental Metastasis, 2015, 32, 55-63.	3.3	62
32	Comment on â€œp38 MAPK inhibition alleviates experimental acute pancreatitis in miceâ€• Hepatobiliary and Pancreatic Diseases International, 2015, 14, 330.	1.3	1
33	Predominant Rab-GTPase amplicons contributing to oral squamous cell carcinoma progression to metastasis. Oncotarget, 2015, 6, 21950-21963.	1.8	27
34	Insights into genetic and epigenetic determinants with impact on vitamin D signaling and cancer association studies: the case of thyroid cancer. Frontiers in Oncology, 2014, 4, 309.	2.8	9
35	The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting. Cancer Medicine, 2014, 3, 14-24.	2.8	28
36	Neurotherapeutic effects of novel <scp>HO</scp>â€1 inhibitors in vitro and in a transgenic mouse model of Alzheimer's disease. Journal of Neurochemistry, 2014, 131, 778-790.	3.9	45

#	Article	IF	Citations
37	TWIST1 is a molecular marker for a poor prognosis in oral cancer and represents a potential therapeutic target. Cancer, 2014, 120, 352-362.	4.1	52
38	Cooverexpression of ERBB1 and ERBB4 receptors predicts poor clinical outcome in pN+ oral squamous cell carcinoma with extranodal spread. Clinical and Experimental Metastasis, 2014, 31, 307-316.	3.3	17
39	Dynamin 2 interacts with connexin 26 to regulate its degradation and function in gap junction formation. International Journal of Biochemistry and Cell Biology, 2014, 55, 288-297.	2.8	8
40	Recurrent Oral Cancer: Current and Emerging Therapeutic Approaches. Frontiers in Pharmacology, 2012, 3, 149.	3.5	98
41	Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases. European Journal of Medicinal Chemistry, 2012, 48, 143-152.	5.5	65
42	Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. Journal of Experimental Medicine, 2010, 207, 2421-2437.	8.5	146
43	Fascin Regulates Prostate Cancer Cell Invasion and Is Associated with Metastasis and Biochemical Failure in Prostate Cancer. Clinical Cancer Research, 2009, 15, 1376-1383.	7.0	91
44	A Novel Experimental Heme Oxygenase-1â€“Targeted Therapy for Hormone-Refractory Prostate Cancer. Cancer Research, 2009, 69, 8017-8024.	0.9	110
45	Serum Proteomic Approach for the Identification of Serum Biomarkers Contributed by Oral Squamous Cell Carcinoma and Host Tissue Microenvironment. Journal of Proteome Research, 2009, 8, 2173-2185.	3.7	68
46	Focal Adhesion Kinase-Related Proline-Rich Tyrosine Kinase 2 and Focal Adhesion Kinase Are Co-Overexpressed in Early-Stage and Invasive ErbB-2-Positive Breast Cancer and Cooperate for Breast Cancer Cell Tumorigenesis and Invasiveness. American Journal of Pathology, 2008, 173, 1540-1550.	3.8	57
47	A Cell Proteomic Approach for the Detection of Secretable Biomarkers of Invasiveness in Oral Squamous Cell Carcinoma. JAMA Otolaryngology, 2007, 133, 910.	1.2	22
48	A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells. Prostate, 2006, 66, 1151-1161.	2.3	43
49	Proteomic technology for biomarker profiling in cancer: an update. Journal of Zhejiang University: Science B, 2006, 7, 411-420.	2.8	42
50	Clinically relevant oral cancer model for serum proteomic eavesdropping on the tumour microenvironment. The Journal of Otolaryngology, 2006, 35, 157-66.	0.6	6
51	FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. Journal of Cell Biology, 2005, 171, 505-516.	5.2	126
52	Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling. Drug Resistance Updates, 2004, 7, 245-255.	14.4	30
53	The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery. Drug Resistance Updates, 2003, 6, 95-107.	14.4	18
54	Unexpected Induction of the Human Connexin 43 Promoter by the Ras Signaling Pathway Is Mediated by a Novel Putative Promoter Sequence. Molecular Pharmacology, 2003, 63, 821-831.	2.3	56

#	Article	IF	Citations
55	Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors. Cancer Research, 2003, 63, 3764-74.	0.9	33
56	Retroviral Delivery of Connexin Genes to Human Breast Tumor Cells Inhibits in Vivo Tumor Growth by a Mechanism That Is Independent of Significant Gap Junctional Intercellular Communication. Journal of Biological Chemistry, 2002, 277, 29132-29138.	3.4	187
57	Differential Regulation of Tumor Angiogenesis by Distinct ErbB Homo- and Heterodimers. Molecular Biology of the Cell, 2002, 13, 4029-4044.	2.1	124
58	Regulation of E-cadherin/catenin complex patterns by epidermal growth factor receptor modulation in human lung cancer cells. Lung Cancer, 2002, 37, 49-56.	2.0	48
59	Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells. Oncogene, 2002, 21, 2634-2640.	5.9	204
60	Upregulation of gap junctional intercellular communication and connexin 43 expression by cyclic-AMP and all- trans -retinoic acid is associated with glutathione depletion and chemosensitivity in neuroblastoma cells. Cancer Chemotherapy and Pharmacology, 2001, 47, 126-132.	2.3	42
61	Action of Low Calcemic 1Â,25-Dihydroxyvitamin D3 Analogue EB1089 in Head and Neck Squamous Cell Carcinoma. Journal of the National Cancer Institute, 2001, 93, 745-753.	6.3	69
62	Cloning and Characterization of a Novel Gene That Is Regulated by Estrogen and Is Associated with Mammary Gland Carcinogenesis*. Endocrinology, 2001, 142, 2409-2418.	2.8	22
63	A Novel Parasite-Derived Suicide Gene for Cancer Gene Therapy with Specificity for Lung Cancer Cells. Human Gene Therapy, 2001, 12, 1673-1680.	2.7	8
64	Cloning and Characterization of a Novel Gene That Is Regulated by Estrogen and Is Associated with Mammary Gland Carcinogenesis. Endocrinology, 2001, 142, 2409-2418.	2.8	8
65	Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene, 2000, 19, 3460-3469.	5.9	224
66	Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells. Oncogene, 1998, 17, 3177-3186.	5.9	27
67	Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185erbB-2 is dependent on the ras signaling pathway. Oncogene, 1997, 14, 1827-1835.	5.9	40
68	Allele-specific PCR analysis ofp53 codon 249 AGT transversion in liver tissues from patients with viral hepatitis. , 1996, 68, 21-25.		28
69	Effect of DNA-repair-enzyme modulators on cytotoxicity ofl-phenylalanine mustard andcis-diamminedichloroplatinum (II) in mammary carcinoma cells resistant to alkylating drugs. Cancer Chemotherapy and Pharmacology, 1994, 34, 153-158.	2.3	24
70	Lack of cross-resistance to a new cytotoxic arylchloroethyl urea in various drug-resistant tumor cells. Cancer Chemotherapy and Pharmacology, 1994, 33, 489-492.	2.3	26